한글목차

PD-1 및 PD-L1억제제/면역관문억제제 시장 규모는 최근 급성장하고 있습니다. 2025년 524억 9,000만 달러에서 2026년에는 598억 3,000만 달러에 이르고, CAGR 14.0%의 성장이 전망되고 있습니다. 지난 수년간의 성장에는 전 세계 암 환자 증가, PD-1 및 PD-L1 억제제의 초기 임상시험 성공, 종양학 분야 R&D에 대한 적극적인 투자, 1세대 체크포인트 억제제의 규제 당국 승인, 암 치료에 대한 의료비 지출 증가 등이 주요 요인으로 꼽히고 있습니다.

PD-1 및 PD-L1억제제/면역관문억제제 시장 규모는 향후 몇 년간 급성장이 전망됩니다. 2030년에는 1,032억 7,000만 달러에 이르고, CAGR은 14.6%를 나타낼 전망입니다. 예측 기간 동안 성장 요인으로는 맞춤 암 치료에 대한 수요 증가, 병용요법 임상시험 확대, 신흥 시장에서의 승인 증가, 환자 생존율 개선, 고형암 및 혈액 악성 종양에서의 채택 증가 등을 꼽을 수 있습니다. 주요 동향으로는 병용 면역요법 요법의 확대, 바이오마커에 기반한 환자 선택 확산, 여러 암 적응증에 대한 승인 증가, 조기 치료 단계에서의 채택 확대, 차세대 체크포인트 억제제의 강력한 파이프라인 등을 꼽을 수 있습니다.

암 환자 증가 추세는 향후 몇 년간 PD-1 및 PD-L1 억제제/면역관문억제제 시장의 성장을 견인할 것으로 예측됩니다. 암은 비정상적인 세포가 통제할 수 없을 정도로 증식하여 체내 다른 부위로 전이되는 질환입니다. PD-1 및 PD-L1 억제제는 체내 면역체계를 활성화시켜 암세포를 인식하고 공격하게 함으로써 암 치료에 사용됩니다. 따라서 암 환자 증가는 PD-1 및 PD-L1 억제제/면역관문억제제 시장 확대에 기여하고 있습니다. 예를 들어, 2024년 2월 스위스에 본부를 둔 국제기구인 세계보건기구(WHO)가 발표한 예측에 따르면, 2050년까지 전 세계적으로 3,500만 명 이상의 새로운 암 환자가 발생할 것으로 예상되며, 이는 2022년에 보고된 약 2,000만 명에 비해 77% 증가한 수치입니다. 증가하게 됩니다. 따라서 암 발병률 증가는 PD-1 및 PD-L1 억제제/면역관문억제제 시장의 성장을 가속하고 있습니다.

PD-1 및 PD-L1 억제제/면역관문억제제 시장에서 활동하는 주요 기업들은 치료 효과를 개선하고 환자 접근성을 확대하기 위한 첨단 면역항암제 솔루션 개발에 주력하고 있습니다. 면역종양학 치료는 건강한 조직의 손상을 최소화하면서 체내 면역체계를 활용해 암세포를 식별하고 파괴하는 치료법입니다. 예를 들어, 2023년 9월 중국 종양학 기업 바이젠(BeiGene)은 노바티스로부터 PD-1 억제제 티쎌리주맙(상품명: 테빔브라)에 대한 권리를 되찾아 유럽에서 기 치료된 식도 편평상피암 치료제로 도입했습니다. 이 치료법은 1차 치료와 2차 치료 모두에서 가능성을 보여주고 있으며, 백건은 가격 책정 및 상업화 전략을 완전히 장악하고 있습니다. 티쎄렐리주맙에 대한 진행 중인 임상시험에는 전이성 비소세포폐암 환자를 대상으로 한 오시페리맙과 화학요법과의 병용요법에 대한 3상 시험과 대장암 환자를 대상으로 한 LAG-3 억제제와의 병용요법에 대한 중간 단계 시험이 포함되어 있습니다. 이는 경쟁이 치열한 면역관문억제제 시장에서 병용요법과 확장 가능한 상업화 접근법에 대한 관심이 높아지고 있음을 반영합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

PD-1 and PD-L1 inhibitors, also known as immune checkpoint inhibitors, are a class of immunotherapy drugs used in the treatment of cancer. They act by targeting the immune system to enhance its ability to recognize and destroy cancer cells and are widely used in the management of various types of cancer.

The key PD-1 and PD-L1 inhibitor products include nivolumab, pembrolizumab, atezolizumab, avelumab, and durvalumab. Nivolumab is a PD-1 inhibitor that functions by blocking the PD-1 receptor on T cells, thereby preventing cancer cells from escaping immune system detection and attack. PD-1 and PD-L1 inhibitors are used in the treatment of lung cancer, bladder cancer, melanoma, Hodgkin lymphoma, colorectal cancer, and other cancers. These drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and are utilized by hospitals, specialty clinics, and academic and research institutions.

Tariffs have created both challenges and strategic shifts in the PD-1 and PDL1 inhibitors market by increasing the cost of imported active pharmaceutical ingredients, biologics manufacturing inputs, and cold-chain logistics. These impacts are most pronounced across branded biologics segments such as nivolumab and pembrolizumab, with Asia-Pacific and Europe being more affected due to cross-border supply dependencies. Higher tariffs can pressure pricing and reimbursement dynamics in hospital pharmacies and public healthcare systems. However, tariffs are also encouraging localized biologics manufacturing, technology transfers, and regional production hubs, which may strengthen long-term supply security and domestic pharmaceutical capabilities.

The pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market research report is one of a series of new reports from The Business Research Company that provides pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market statistics, including pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors industry global market size, regional shares, competitors with a pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market share, detailed pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors industry. This pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market size has grown rapidly in recent years. It will grow from $52.49 billion in 2025 to $59.83 billion in 2026 at a compound annual growth rate (CAGR) of 14.0%. The growth in the historic period can be attributed to increasing global cancer prevalence, early clinical success of PD-1 and PDL1 inhibitors, strong investment in oncology R&D, regulatory approvals for first-generation checkpoint inhibitors, rising healthcare expenditure on cancer therapies.

The pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market size is expected to see rapid growth in the next few years. It will grow to $103.27 billion in 2030 at a compound annual growth rate (CAGR) of 14.6%. The growth in the forecast period can be attributed to growing demand for personalized cancer treatment, expanding clinical trials for combination therapies, increasing approvals in emerging markets, improved patient survival outcomes, rising adoption in solid and hematological malignancies. Major trends in the forecast period include expansion of combination immunotherapy regimens, growing use of biomarker-based patient selection, increasing approvals across multiple cancer indications, rising adoption in earlier lines of cancer treatment, strong pipeline of next-generation checkpoint inhibitors.

The increasing prevalence of cancer cases is expected to drive the growth of the PD-1 and PD-L1 inhibitors/immune checkpoint inhibitors market in the coming years. Cancer is a disease in which abnormal cells grow uncontrollably and can spread to other parts of the body. PD-1 and PD-L1 inhibitors are used in cancer treatment by activating the body's immune system to recognize and attack cancer cells. As a result, the growing number of cancer cases is contributing to the expansion of the PD-1 and PD-L1 inhibitors/immune checkpoint inhibitors market. For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, more than 35 million new cancer cases are projected globally by 2050, representing a 77% increase compared to the estimated 20 million cases reported in 2022. Therefore, the rising prevalence of cancer is fueling the growth of the PD-1 and PD-L1 inhibitors/immune checkpoint inhibitors market.

Leading companies operating in the PD-1 and PD-L1 inhibitors/immune checkpoint inhibitors market are focusing on the development of advanced immuno-oncology solutions to improve treatment effectiveness and expand patient access. Immuno-oncology therapies leverage the body's immune system to identify and destroy cancer cells while minimizing damage to healthy tissues. For example, in September 2023, BeiGene, a China-based oncology company, regained full rights to the PD-1 inhibitor tislelizumab from Novartis and introduced it in Europe under the brand name Tevimbra for the treatment of previously treated esophageal squamous cell carcinoma. The therapy has shown potential in both first-line and second-line settings and provides BeiGene with full control over pricing and commercialization strategies. Ongoing clinical trials of tislelizumab include a phase 3 study combining it with ociperlimab and chemotherapy for metastatic non-small cell lung cancer, as well as a mid-stage study in combination with a LAG-3 agent for colorectal cancer, reflecting the increasing focus on combination therapies and scalable commercialization approaches within the competitive immune checkpoint inhibitor market.

In June 2023, Coherus BioSciences, a US-based biopharmaceutical company specializing in cancer therapeutics, acquired Surface Oncology for $65 million. This acquisition broadened Coherus' portfolio by incorporating novel immuno-oncology assets, including Surface Oncology's IL-27-targeted antibody SRF388 and CCR8-targeted antibody SRF114. Through this transaction, Coherus expanded its pipeline with a diverse range of clinical-stage immunotherapies designed to enhance anti-tumor immune responses, including applications in lung and liver cancers. Surface Oncology is a US-based company involved in the development of PD-1 and PD-L1 inhibitors, which play a key role in immune checkpoint-based cancer therapies.

Major companies operating in the pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market are Bristol-Myers Squibb Company, Merck and Company, F. Hoffmann-La Roche AG, Amgen Inc., AstraZeneca plc, Pfizer Inc., Regeneron Pharmaceuticals Inc., BeiGene Ltd, Shanghai Jhunsi Biosciences Ltd., Akeso Inc., Alphamab Oncology, Eli Lilly and Company, Xencor Inc., Jiangsu Alphamab Biopharmaceuticals Co. Ltd, Laekna Therapeutics, Genentech Inc., Tracon Pharmaceuticals Inc., Hangzhou Sumgen Co. Ltd, Agenus Inc., Celldex Therapeutics Inc., CytomX Therapeutics Inc.

North America was the largest region in the PD-1 and PDL1 inhibitors market in 2025. The regions covered in the pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The PD-1 and PDL1 Inhibitors/ Immune checkpoint inhibitors market consists of sales of various inhibitors such as cemiplimab, sintilimab, and camrelizumab. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product: Nivolumab; Pembrolizumab; Atezolizumab; Avelumab; Durvalumab
• 2) By Distribution Channel: Hospital pharmacies; Retail pharmacies; Online pharmacies
• 3) By Application: Lung Cancer; Bladder Cancer; Melanoma; Hodgkin Lymphoma; Colorectal Cancer; Other Applications
• 4) By End-Users : Hospitals; Specialty Clinics; Academic and Research Institutions
• Companies Mentioned: Bristol-Myers Squibb Company; Merck and Company; F. Hoffmann-La Roche AG; Amgen Inc.; AstraZeneca plc; Pfizer Inc.; Regeneron Pharmaceuticals Inc.; BeiGene Ltd; Shanghai Jhunsi Biosciences Ltd.; Akeso Inc.; Alphamab Oncology; Eli Lilly and Company; Xencor Inc.; Jiangsu Alphamab Biopharmaceuticals Co. Ltd; Laekna Therapeutics; Genentech Inc.; Tracon Pharmaceuticals Inc.; Hangzhou Sumgen Co. Ltd; Agenus Inc.; Celldex Therapeutics Inc.; CytomX Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Expansion Of Combination Immunotherapy Regimens
  • 4.2.2 Growing Use Of Biomarker-Based Patient Selection
  • 4.2.3 Increasing Approvals Across Multiple Cancer Indications
  • 4.2.4 Rising Adoption In Earlier Lines Of Cancer Treatment
  • 4.2.5 Strong Pipeline Of Next-Generation Checkpoint Inhibitors

5. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Clinics
• 5.3 Cancer Treatment Centers
• 5.4 Academic And Research Institutions
• 5.5 Oncology Research Laboratories

6. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Segmentation

• 9.1. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Nivolumab, Pembrolizumab, Atezolizumab, Avelumab, Durvalumab
• 9.2. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
• 9.3. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Lung Cancer, Bladder Cancer, Melanoma, Hodgkin Lymphoma, Colorectal Cancer, Other Applications
• 9.4. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Specialty Clinics, Academic And Research Institutions

10. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Regional And Country Analysis

• 10.1. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 11.1. Asia-Pacific PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 12.1. China PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 13.1. India PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 14.1. Japan PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 15.1. Australia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 16.1. Indonesia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 17.1. South Korea PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 18.1. Taiwan PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 19.1. South East Asia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 20.1. Western Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 21.1. UK PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 22.1. Germany PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 23.1. France PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 24.1. Italy PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 25.1. Spain PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 26.1. Eastern Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 27.1. Russia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 28.1. North America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 29.1. USA PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 30.1. Canada PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 31.1. South America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 32.1. Brazil PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 33.1. Middle East PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 34.1. Africa PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Segmentation By Distribution Channel, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Regulatory and Investment Landscape

36. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Competitive Landscape And Company Profiles

• 36.1. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Company Profiles
  • 36.3.1. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Merck and Company Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

37. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Other Major And Innovative Companies

• Pfizer Inc., Regeneron Pharmaceuticals Inc., BeiGene Ltd, Shanghai Jhunsi Biosciences Ltd., Akeso Inc., Alphamab Oncology, Eli Lilly and Company, Xencor Inc., Jiangsu Alphamab Biopharmaceuticals Co. Ltd, Laekna Therapeutics, Genentech Inc., Tracon Pharmaceuticals Inc., Hangzhou Sumgen Co. Ltd, Agenus Inc., Celldex Therapeutics Inc.

38. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

40. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market High Potential Countries, Segments and Strategies

• 40.1 PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market In 2030 - Countries Offering Most New Opportunities
• 40.2 PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market In 2030 - Segments Offering Most New Opportunities
• 40.3 PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer